{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'not limited to, topotecan.) The Investigator should consult with the Medical Monitor', 'if necessary.', '15. Current or expected use of phosphodiesterase-4 inhibitors (e.g. roflumilast).', 'Participants currently receiving roflumilast may be included if they are able to', 'discontinue use from 30 days prior to screening through the completion of the follow', 'up visit.', 'Prior/Concurrent Clinical Study Experience', '16. Participation in a previous clinical trial and has received an investigational product', 'within any of the following time periods prior to the first dosing day in the current', 'study: 30 days, 5 half lives, or twice the duration of the biological effect of the', 'investigational product (whichever is longer).', '17. Participation in a previous clinical trial with danirixin within 1 year prior to the first', 'dosing day in the current study', '18. Exposure to more than four investigational products within 1 year prior to the first', 'dosing day in the current study.', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN); bilirubin > 1.5xULN', '(isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct', 'bilirubin <35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Other Exclusions', '22. Pulmonary rehabilitation: Participants who have taken part in the acute phase of a', 'pulmonary rehabilitation program within 4 weeks prior to screening or participants', 'who plan to enter the acute phase of a pulmonary rehabilitation program during the', 'study. Participants who are in the maintenance phase of a pulmonary rehabilitation', 'program are not excluded.', '23. A history of allergy or hypersensitivity to any of the ingredients in the study', 'treatment.', '24. A known or suspected history of alcohol or drug abuse within the 2 years prior to', 'screening.', '25. Inability to read: in the opinion of the Investigator, any participant who is unable to', 'read and/or would not be able to complete study related materials.', '26. Affiliation with the study site: study investigators, sub-investigators, study', 'coordinators, employees of a study investigator, sub-investigator or study site, or', 'immediate family member of any of the above that are involved with the study.', '25']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '6.3.', 'Lifestyle Restrictions', '6.3.1.', 'Meals and Dietary Restrictions', 'No meal or dietary restrictions are required for participation in this study. Danirixin must', 'be taken with food. Specific dosing instructions will be provided in the Study Reference', 'Manual (SRM) and will be provided to all study participants.', '6.3.2.', 'Activity', 'Participants should abstain from strenuous exercise for 24 hours before each blood', 'collection for clinical laboratory tests.', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently randomized in the study. A minimal set of screen failure', 'information is required to ensure transparent reporting of screen failure participants to', 'meet the Consolidated Standards of Reporting Trials (CONSORT) publishing', 'requirements and to respond to queries from regulatory authorities. Minimal information', 'includes demography, screen failure details, eligibility criteria and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may not be rescreened unless discussed with the medical monitor.', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s),', 'placebo, or medical device(s) intended to be administered to a study participant according', 'to the study protocol.', '26']\n\n###\n\n", "completion": "END"}